Literature DB >> 25352868

Glycosylated haemoglobin is markedly elevated in new and known diabetes patients with hyperglycaemic ketoacidosis.

Chukwuma O Ekpebegh1, Benjamin Longo-Mbenza1, Ernesto Blanco-Blanco2.   

Abstract

BACKGROUND: Glycosylated haemoglobin (HbA1c) and random blood glucose are markers of chronic and acute hyperglycaemia respectively.
OBJECTIVE: We compared HbA1c levels in ketoacidosis (DKA) occurring in known and newly diagnosed diabetes.
METHODS: Retrospective review of medical records for 83 DKA admissions in 2008 and 2009 with results for HbA1c at presentation.
RESULTS: There were 52 and 31 DKA admissions in known and newly diagnosed diabetes patients respectively. Fifty of the 83 DKA admissions were in females. The mean age (per admissions) and HbA1c of all admissions are 43.4 ± 20.3 years (n=83) and 12.7 ± 3.4 % (n=83) respectively. Mean HbA1c in known Type 1, known Type 2 and newly diagnosed diabetes patients were similarly very high: 12.4 ± 3.3 %, 12.5 ± 3.3 %, 13.1 ± 3.7 %; P = 0.6828. The HbA1c levels in newly diagnosed diabetes patients less than 30 years (likely Type 1 diabetes) and ≥ 30 years (likely Type 2 diabetes) were similar. There was a tendency to significantly positive correlation between blood glucose and HbA1c in new diabetes patients.
CONCLUSIONS: In our setting, DKA is associated with markedly elevated HbA1c levels in known type 1, known type 2 and new onset diabetes.

Entities:  

Keywords:  Glycosylated haemoglobin; Known and newly diagnosed diabetes; ketoacidosis

Mesh:

Substances:

Year:  2014        PMID: 25352868      PMCID: PMC4209657          DOI: 10.4314/ahs.v14i3.5

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  16 in total

Review 1.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

2.  Ketoacidosis at diagnosis is predictive of lower residual beta-cell function and poor metabolic control in type 1 diabetes.

Authors:  M Fernandez Castañer; E Montaña; I Camps; J Biarnes; J F Merino; J M Escriba; V Nacher; P Rosel; J Soler
Journal:  Diabetes Metab       Date:  1996-10       Impact factor: 6.041

3.  Clinical, immunologic and insulin secretory characteristics of young black South African patients with diabetes: Hospital based single centre study.

Authors:  C O Ekpebegh; B Longo-Mbenza
Journal:  Diabetes Res Clin Pract       Date:  2013-01-05       Impact factor: 5.602

4.  Immunogenetic analysis suggests different pathogenesis for obese and lean African-Americans with diabetic ketoacidosis.

Authors:  G E Umpierrez; W Woo; W A Hagopian; S D Isaacs; J P Palmer; L K Gaur; G T Nepom; W S Clark; P S Mixon; A E Kitabchi
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

5.  Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics.

Authors:  David C Henderson; Enrico Cagliero; Paul M Copeland; Pearl M Louie; Christina P Borba; Xiaoduo Fan; Oliver Freudenreich; Donald C Goff
Journal:  J Clin Psychiatry       Date:  2007-04       Impact factor: 4.384

6.  International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2009-06-05       Impact factor: 17.152

7.  Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus: clinical and biochemical differences.

Authors:  Christopher A Newton; Philip Raskin
Journal:  Arch Intern Med       Date:  2004-09-27

8.  Measuring the quality of care of diabetic patients at the specialist outpatient clinics in public hospitals in Singapore.

Authors:  Matthias P H S Toh; Bee Hoon Heng; Chee Fang Sum; Michelle Jong; Siok Bee Chionh; Jason T S Cheah
Journal:  Ann Acad Med Singapore       Date:  2007-12       Impact factor: 2.473

9.  Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistance.

Authors:  Franck Mauvais-Jarvis; Eugène Sobngwi; Raphaël Porcher; Jean-Pierre Riveline; Jean-Philippe Kevorkian; Christian Vaisse; Guillaume Charpentier; Pierre-Jean Guillausseau; Patrick Vexiau; Jean-François Gautier
Journal:  Diabetes       Date:  2004-03       Impact factor: 9.461

10.  Diabetic subjects diagnosed through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset.

Authors:  Taylor M Triolo; H Peter Chase; Jennifer M Barker
Journal:  Diabetes Care       Date:  2009-05       Impact factor: 17.152

View more
  6 in total

1.  Ebola and other issues in the health sector in Africa.

Authors:  J K Tumwine
Journal:  Afr Health Sci       Date:  2014-09       Impact factor: 0.927

2.  Should haemoglobin A1C be used for diagnosis of diabetes mellitus in Malawi?

Authors:  W P Nakanga; A Crampin; M Nyirenda
Journal:  Malawi Med J       Date:  2016-03       Impact factor: 0.875

3.  HbA1c as a Screening tool for Ketosis in Patients with Type 2 Diabetes Mellitus.

Authors:  Bing Zhu; Le Bu; Manna Zhang; Aaron M Gusdon; Liang Zheng; Sharvan Rampersad; Jue Li; Shen Qu
Journal:  Sci Rep       Date:  2016-12-23       Impact factor: 4.379

4.  The management of diabetic ketoacidosis at a rural regional hospital in KwaZulu-Natal.

Authors:  Nontobeko F M Ndebele; Mergan Naidoo
Journal:  Afr J Prim Health Care Fam Med       Date:  2018-03-22

Review 5.  Diabetes and COVID-19; A Bidirectional Interplay.

Authors:  Paraskevi Kazakou; Vaia Lambadiari; Ignatios Ikonomidis; Aikaterini Kountouri; Georgios Panagopoulos; Stavros Athanasopoulos; Eleni Korompoki; Ioannis Kalomenidis; Meletios A Dimopoulos; Asimina Mitrakou
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-17       Impact factor: 5.555

6.  The Examination of the Relationship Between COVID-19 and New-Onset Type 1 Diabetes Mellitus in Children.

Authors:  Zeynep Donbaloğlu; Hale Tuhan; Tuğçe Tural Kara; Aynur Bedel; Ebru Barsal Çetiner; Berna Singin; Mesut Parlak
Journal:  Turk Arch Pediatr       Date:  2022-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.